Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture  by Rouquette, Magali et al.
Xanthine oxidoreductase is asymmetrically localised on the outer surface
of human endothelial and epithelial cells in culture
Magali Rouquettea, Susanna Pagea, Richard Bryanta, Mustapha Benboubetraa,
Cli¡ R. Stevensb, David R. Blakeb, William D. Whisha, Roger Harrisona;*, David Tosha
aDepartment of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK
bDepartment of Postgraduate Medicine, University of Bath, Bath BA2 7AY, UK
Received 19 March 1998
Abstract Subcellular localisation of xanthine oxidoreductase
(XOR) was determined by indirect immunofluorescence using
confocal microscopy in human endothelial and epithelial cell lines
and in primary cultures of human umbilical vein endothelial cells.
XOR was diffusely distributed throughout the cytoplasm but with
higher intensity in the perinuclear region. In non-permeabilised
cells, XOR was clearly seen to be asymmetrically located on the
outer surfaces, showing, in many cases, a higher intensity on
those faces apposed by closely neighbouring cells. Such specific
distribution suggests a functional role for the enzyme in cell-cell
interactions, possibly involving signalling via reactive oxygen
species
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1. Introduction
Xanthine oxidoreductase (XOR) is a molybdenum-contain-
ing £avoenzyme that catalyses the hydroxylation of hypoxan-
thine to xanthine and of xanthine to uric acid in the latter
stages of purine catabolism [1]. In mammals, it occurs in two
interconvertible forms, xanthine dehydrogenase (EC 1.1.1.204)
and xanthine oxidase (EC 1.1.3.22). Both forms of the enzyme
can reduce molecular oxygen, although only the dehydrogen-
ase form can reduce NAD, which it prefers as an electron
acceptor. Reduction of oxygen leads to superoxide anion
and hydrogen peroxide and it is the potential to generate these
reactive oxygen species that has led to widespread interest in
the enzyme as a pathogenic agent in many forms of ischae-
mia-reperfusion injury [2]. More recently, reactive oxygen spe-
cies are being increasingly cited as intermediates in normal
signal transduction pathways [3,4].
XOR is widely distributed, being particularly rich in mam-
mary epithelial cells and in capillary endothelium in a range of
tissues [5,6]. While the enzyme is generally understood to be
cytosolic, there have been very few published investigations of
its precise subcellular localisation. Jarasch et al. [5] used both
light and electron microscopic immunohistochemical proce-
dures to show that XOR is located throughout the cytoplasm
of bovine capillary endothelial cells. This was also found to be
the case in rat liver endothelial cells [7,8]. In contrast, using
immunoelectron microscopy, Ichikawa et al. [9] concluded
that the enzyme was exclusively cytosolic with no signi¢cant
association with intracellular organelles, including endoplas-
mic reticulum, Golgi apparatus, lysosomes or peroxisomes.
The apparent confusion over the subcellular location of
XOR prompted us to investigate the situation in human cells.
The human enzyme is of especial interest, particularly in view
of questions regarding its anomalous characteristics and phys-
iological role [10]. We have, accordingly, made use of confocal
microscopy in immunolocalisation of the enzyme in human
endothelial and epithelial cells in culture. We show here that
XOR is present not only in the cytoplasm but also on the
outer surface of all three cell types studied. Moreover, the
extracellular enzyme shows a strongly polarised distribution,
being in many cases concentrated on those surfaces closely
apposed by neighbouring cells.
2. Materials and methods
2.1. Materials
RPMI 1640 culture medium was obtained from ICN, Costa Mesa,
CA, USA. Penicillin, streptomycin and foetal calf serum (FCS) were
from Life Technologies, Paisley, UK. Rabbit anti-TGN 46 antibody
was a kind gift from Dr. George Banting (Department of Biochemis-
try, University of Bristol, UK). Rabbit anti-(bovine milk XOR) was
from Chemicon International, Harrow, UK. All other reagents, unless
otherwise stated, were from Sigma, Poole, UK.
2.2. Cell culture
EA-hy-926, a permanent endothelial cell line [11], was a gift from
Dr. Andrew George, Imperial College School of Medicine, Hammer-
smith Hospital, London. The cells were routinely grown in an atmos-
phere of 5% CO2/95% air in 75-cm2 £asks at 37‡C, as previously
described [12]. Growth medium, RPMI 1640, containing 10% (v/v)
FCS and penicillin/streptomycin [12], was changed every 3^4 days.
The cells grew to form a con£uent monolayer after approximately
7 days, exhibiting typical endothelial cell characteristics and were
shown, by immuno£uorescence (results not shown), to be positive
for factor VIII, as reported by Edgell et al. [11].
HB4a is a human mammary epithelial cell line, conditionally im-
mortalised by transfection with SV40 virus [13] and kindly donated to
us by Dr T. Kamalati and Professor B. Gusterson of the Institute for
Cancer Research, Royal Cancer Hospital, Sutton, UK. HB4a cells
were routinely grown at 37‡C in 75-cm2 culture £asks, in an atmos-
phere of 5% CO2/95% air as previously described [14]. Growth me-
dium, RPMI 1640 containing 10% (v/v) FCS and other supplements
[14], was changed every 3^4 days. Cells grew to con£uence, forming a
strict monolayer after 9 days, showing a characteristic ‘crazy paving’
appearance and stained strongly positive (results not shown) for the
epithelial cell marker, cytokeratin [14].
Human umbilical vein endothelial cells (HUVECs) were obtained
from human umbilical veins (kindly donated by the nursing sta¡ of
the Princess Anne Wing, Royal United Hospitals, Bath) and cultured
essentially as described by Ja¡e et al. [15].
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2.3. Immunolabelling of cells and confocal microscopy
Cells were seeded (approx. 2U105 cells/ml) in four-chambered glass
slides (Nunc Inc., Naperville, IL, USA), incubated for 24 h at 37‡C
and washed twice with pre-warmed PBS before ¢xing for 20 min at
room temperature with 4% (w/v) formaldehyde in PBS.
Cells were permeabilised by incubation with 0.1% (w/v) saponin in
PBS for 45 min, then incubated with rabbit polyclonal anti-(human
XOR) antibodies in PBS (0.02 mg/ml), containing 0.1% (w/v) saponin,
3% (v/v) normal goat serum and 1% (w/v) BSA, for 2 h at room
temperature. The cells were washed three times with 0.1% (w/v) sap-
onin in PBS before incubation, for 2 h at room temperature, with
secondary antibody [FITC-conjugated goat anti-rabbit IgG (0.025 mg/
ml, Jackson Immunoresearch Labs. Inc., West Grove, PA, USA)],
diluted 1:100 in the same diluant as for the primary antibodies. The
cells were then washed three times with PBS containing 0.1% (w/v)
saponin, before removing the chambers from the slides prior to con-
focal microscopy.
Unpermeabilised cells were obtained and treated as above, except
that saponin was omitted throughout.
The permeabilised or unpermeabilised nature of the cells was con-
¢rmed by immunolabelling with rabbit anti-TGN 46 antibody, which
is speci¢c for the trans-Golgi network (results not shown) [16].
Images were collected on a confocal laser-scanning microscope
(LSM 510, with either U40 1.30 NA or U63 1.40 NA apochromatic
objective; Carl Zeiss, Welwyn Garden, UK). The 488 lines of an
argon laser were used for excitation of FITC.
2.4. Assay for XOR enzymic activity
Cell extracts were prepared and assayed for total (oxidase plus
dehydrogenase) activity as previously described [14], using a sensitive
£uorimetric procedure [17]. EA-hy-926 and HB4a cells contained 1^2
pmol isoxanthopterin/min/mg. Activity of HUVECs was below the
lower limit of sensitivity of the assay (0.1 pmol isoxanthopterin/min/
mg).
2.5. Heparin-Sepharose treatment of growth medium
A column (3.5 cmU1.5 cm) of heparin-Sepharose (Sigma) was
washed with appropriate growth medium (30 ml) lacking FCS.
Growth medium (100 ml) containing FCS (10%) was then passed
through the column and collected in a sterile container. The column
was washed with 25 mM sodium phosphate bu¡er, pH 7.4, until A280
reached a baseline level, and then with the same bu¡er containing 1 M
NaCl. Protein-containing fraction (A280) was assayed for XOR enzy-
mic activity as described above.
2.6. Generation and a⁄nity puri¢cation of rabbit polyclonal
anti-(human XOR) antibodies
Antibodies were generated and a⁄nity-puri¢ed as previously de-
scribed [14]. Their speci¢city has been previously established by im-
munoprecipitation of XOR from HB4a cell extracts [14]. Incubation
of HB4a cell extracts with the gel-bound speci¢c antibodies removed
100% of XOR enzymic activity, while SDS-PAGE of the immunopre-
cipitate showed only the characteristic band of XOR, apart from
bands attributable to the antibodies themselves [14].
3. Results
Three human cell types, including endothelial (EA-hy-926)
and epithelial (HB4a) cell lines and primary endothelial (HU-
VEC) cells in culture, were studied using a⁄nity-puri¢ed rab-
bit anti-(human XOR) antibodies (see Section 2). In all cases,
immunolocalisation of XOR in permeabilised cells showed the
enzyme to be di¡usely distributed throughout the cytoplasm,
although £uorescence in the perinuclear region was more in-
tense (Fig. 1). Immunolocalisation of XOR in unpermeabi-
lised cells clearly showed the presence of the enzyme on the
outer cell surface, the distribution being localised to speci¢c
areas of the cell (Fig. 2). In several cases, XOR appeared to be
concentrated on those parts of the surface that apposed or
were extending towards neighbouring cells (Fig. 2C, arrows).
Use of commercially supplied rabbit anti-(bovine milk
XOR) antibody gave the same results as those described
above (results not shown).
Because of the possibility that XOR on the surface of our
cells in culture originated in the growth medium (which con-
tains FCS) the latter was assayed for XOR. Enzymic activity
could not be detected by the sensitive £uorimetric procedure
(see Section 2). In view of the high a⁄nity of human XOR for
heparin [18,19], we sought to concentrate any small amounts
of XOR in the growth medium by passage down a column of
heparin-Sepharose (see Section 2). In none of six batches of
serum was XOR activity detectable by £uorescence assay
when the heparin column was subsequently eluted with 1 M
NaCl, conditions known to elute the human enzyme [19]. Two
further control experiments addressed this issue. In the ¢rst of
these, parallel cultures of EA-hy-926 or HB4a cells were
grown in 75-cm2 £asks in the corresponding growth medium
that had, or had not been passed down a heparin-Sepharose
column (see Section 2). In each case, cells were then seeded
onto duplicate wells of glass slides as usual and subjected to
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Fig. 1. Distribution of XOR in permeabilised EA-hy-926 cells (A,
B), HB4a cells (C, D) and HUVECs (E, F). For experimental de-
tails see Section 2. Immuno£uorescent (A, C, E) and di¡erential in-
terference contrast (DIC) (B, D, F) images are shown. Magni¢ca-
tion U630 (A, B), U400 (C^F); bar, 20 Wm.
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immunolabelling. No di¡erence was apparent in the distribu-
tion or intensity of the £uorescence patterns between unper-
meabilised cells grown in heparin-treated and untreated me-
dium, nor was there any signi¢cant di¡erence in total XOR
activity in the cells, as assayed £uorimetrically. Results for
EA-hy-926 cells are shown in Fig. 3C^F, in which the polar-
ised distribution of the enzyme is again clearly seen. In the
second control experiment, heparin-Sepharose beads (300 Wl)
were washed twice with PBS before incubation overnight, with
continuous gentle agitation, either with growth medium (con-
taining FCS), PBS or with PBS containing bovine XOR (10
Wg/ml). Subsequent labelling with anti-XOR antibody showed
clear immuno£uorescence on the surface of the beads in the
latter but not the former case (Fig. 3). Similar incubation of
heparin beads with normal goat serum, used as a blocking
agent in immunolabelling, also failed to lead to immuno£uo-
rescence on the surface of the beads.
4. Discussion
While reactive oxygen species are increasingly being consid-
ered as agents of signal transduction [3,4], their source is sel-
dom clear, and XOR, with its capacity for generation of
superoxide anion and hydrogen peroxide, is in many cases
an attractive candidate [10]. The subcellular localisation of
the enzyme is clearly relevant to its function and it is with
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Fig. 2. Distribution of XOR in unpermeabilised EA-hy-926 cells (A^C), HB4a cells (D^F) and HUVECs (G^I). For experimental details see
Section 2. Immuno£uorescent (A, D, G) and DIC (B, E, H) images are overlaid (C, F, I) to emphasise the polarised distribution. Arrows (C)
show examples where £uorescence is concentrated on surfaces that appose those of neighbouring cells. Magni¢cation U400; bar, 20 Wm.
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this in mind that we examined the former in cultured human
cells.
XOR is generally assumed to be a cytoplasmic enzyme,
although its precise localisation is unclear, having been de-
scribed as being both peroxisomal [7,8] and exclusively cyto-
solic [9]. In the permeabilised cells of the present study, XOR
was seen to be generally distributed throughout the cytoplasm
but with more intense staining in the perinuclear region. This
latter localisation has not, to our knowledge, been suggested
previously and has interesting implications concerning possi-
ble functions of the cytoplasmic enzyme. A perinuclear loca-
tion would, for example, accord with a role for XOR as a
source of reactive oxygen species that activate nuclear tran-
scription factors, such as NF-UB [20].
XOR was clearly detected on the outer surface of unper-
meabilised cells of all three human cell types studied. While
extracellular localisation of XOR has previously been pro-
posed in bovine aortic endothelial cells [21,22], our presently
reported ¢ndings constitute the ¢rst detailed evidence of such
a localisation in any cell type. In view of the potential impor-
tance of these results, it was necessary to eliminate the possi-
bility that surface enzyme is derived from exogenous sources,
such as, for example FCS in the growth media. Growth media
did not contain levels of XOR above the limit of sensitivity of
the £uorimetric assay. This, in itself, does not necessarily pre-
clude the presence of lower levels of enzyme. However, XOR
was not detected in the growth media following attempted
concentration of the enzyme by chromatography on hepa-
rin-Sepharose, nor were any di¡erences in immunolabelling
detected when any of the three cell types was grown in pre-
absorbed medium. Moreover, growth medium for all three
cells failed to show £uorescence labelling of heparin-Sephar-
ose beads when incubated with the latter. Similar results were
obtained with goat serum, routinely used as a blocking agent
in immunolabelling. Finally, it is highly unlikely that cell sur-
face XOR originated in lysed neighbouring cells, which are at
low density early in their growth cycle and are essentially
100% viable.
If we accept that the extracellular XOR is indeed an endog-
enous enzyme, then the mechanisms of its secretion come into
question. The classical secretory pathway of protein biosyn-
thesis involves transfer from the endoplasmic reticulum
through the Golgi apparatus to the plasma membrane and
depends upon the presence of a cleavable signal peptide [23].
Human XOR has no signal peptide [24,25] and is not known
to be glycosylated, a consequence of the classical secretory
pathway. However, increasing numbers of polypeptides with
these characteristics, that are nevertheless secreted from both
prokaryotic and eukaryotic cells, are being discovered [26] and
it may well be that XOR is another such protein using a non-
classical secretory pathway. In view of the relatively high af-
¢nity of XOR for heparin [18,19], it is interesting to note an
earlier suggestion [27] that muscle L-14 lectin, exported by a
non-classical pathway, would thus be separated from glyco-
conjugates, with which it interacted, until after its secretion.
Similar considerations could apply to XOR, which may be
expected to bind to cell surface glycosylaminoglycans follow-
ing secretion. It is noteworthy that incubation of EA-hy-926
cells with heparin, followed by washing, failed to signi¢cantly
diminish the intensity of staining (results not shown), suggest-
ing that other glycosylaminoglycans may be involved.
Our results clearly show that XOR is not only present on
the outer surface of cultured human endothelial and epithelial
cells, but is asymmetrically distributed, in many cases appear-
ing to be localised to surfaces apposed to those of closely
neighbouring cells. This extracellular localisation and partic-
ularly its polarised nature strongly suggest a role for XOR in
cell-cell interactions, possibly involving signalling via reactive
oxygen species. We believe this to be an entirely novel concept
worthy of detailed further investigations. Such investigations
are, however, beyond the scope of the present study.
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Fig. 3. Control experiments showing that cell surface XOR is not
derived from growth medium. Heparin beads were incubated for 24
h with growth medium (A) or with PBS containing bovine XOR
(B) (see Section 3). C, D and E, F show EA-hy-926 cells grown in
medium (containing FCS), that has (E, F) or has not (C, D) been
preabsorbed on a heparin-Sepharose column (see Section 2). Immu-
no£uorescence (A^C, E) and DIC (D, F) images were obtained as
described in Section 2. Magni¢cation U100; bar, 50 Wm (A, B);
U400; bar, 20 Wm (C^F).
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